Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in Lancet Oncol Retrieve available abstracts of 112 articles: HTML format Text format

Single Articles

June 2018
1. GOURD E
   Lung cancer incidence higher in US women than men.
   Lancet Oncol. 2018 Jun 1. pii: S1470-2045(18)30422.
   PubMed     Text format    
   
   
   April 2018
2. ROLFO C, Smits ELJ
   Combining top-ranked immunotherapeutics in lung cancer.
   Lancet Oncol. 2018 Apr 5. pii: S1470-2045(18)30186.
   PubMed     Text format    
   
   
   
3. WRANGLE JM, Velcheti V, Patel MR, Garrett-Mayer E, et al
   ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
   Lancet Oncol. 2018 Apr 5. pii: S1470-2045(18)30148.
   PubMed     Text format     Abstract available
   
   
   March 2018
4. LIN JJ, Gainor JF
   ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?
   Lancet Oncol. 2018 Mar 12. pii: S1470-2045(18)30160.
   PubMed     Text format    
   
   
   
5. GARASSINO MC, Cho BC, Kim JH, Mazieres J, et al
   Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
   Lancet Oncol. 2018 Mar 12. pii: S1470-2045(18)30144.
   PubMed     Text format     Abstract available
   
   
   
6. FIELD JK, Heuvelmans MA, Devaraj A, Heussel CP, et al
   Low-dose CT for lung cancer screening - Authors' reply.
   Lancet Oncol. 2018;19:e135-e136.
   PubMed     Text format    
   
   
   
7. BACH PB, Brawley OW, Silvestri GA
   Low-dose CT for lung cancer screening.
   Lancet Oncol. 2018;19:e133-e134.
   PubMed     Text format    
   
   
   
8. RUANO-RAVINA A, Perez-Rios M, Casan-Clara P, Provencio-Pulla M, et al
   Low-dose CT for lung cancer screening.
   Lancet Oncol. 2018;19:e131-e132.
   PubMed     Text format    
   
   
   
9. WU YL, Zhong WZ
   Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply.
   Lancet Oncol. 2018;19:e127.
   PubMed     Text format    
   
   
   
10. ROSELL R, Karachaliou N
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e126.
    PubMed     Text format    
    
    
    
11. MA JA, Jiang S, Hu C, Xie Y, et al
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e125.
    PubMed     Text format    
    
    
    
12. WU F, Liu X, Ma JA, Gao Y, et al
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e124.
    PubMed     Text format    
    
    
    January 2018
13. CHENG H, Perez-Soler R
    Leptomeningeal metastases in non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e43-e55.
    PubMed     Text format     Abstract available
    
    
    December 2017
14. OUDKERK M, Devaraj A, Vliegenthart R, Henzler T, et al
    European position statement on lung cancer screening.
    Lancet Oncol. 2017;18:e754-e766.
    PubMed     Text format     Abstract available
    
    
    
15. EMERY JD, Mitchell PL
    Lung cancer in Asian women and health system implications for Australia.
    Lancet Oncol. 2017;18:1570-1571.
    PubMed     Text format    
    
    
    
16. BRAHMER JR, Rodriguez-Abreu D, Robinson AG, Hui R, et al
    Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
    Lancet Oncol. 2017;18:1600-1609.
    PubMed     Text format     Abstract available
    
    
    
17. FEROLLA P, Brizzi MP, Meyer T, Mansoor W, et al
    Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
    Lancet Oncol. 2017;18:1652-1664.
    PubMed     Text format     Abstract available
    
    
    November 2017
18. WEISS J
    Bevacizumab in adjuvant treatment of non-small-cell lung cancer.
    Lancet Oncol. 2017 Nov 9. pii: S1470-2045(17)30843.
    PubMed     Text format    
    
    
    
19. WAKELEE HA, Dahlberg SE, Keller SM, Tester WJ, et al
    Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
    Lancet Oncol. 2017 Nov 9. pii: S1470-2045(17)30691.
    PubMed     Text format     Abstract available
    
    
    October 2017
20. SHAW AT, Felip E, Bauer TM, Besse B, et al
    Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Lancet Oncol. 2017 Oct 23. pii: S1470-2045(17)30680.
    PubMed     Text format     Abstract available
    
    
    
21. DE KONING HJ
    Lung cancer screening and its continuous risk assessment.
    Lancet Oncol. 2017 Oct 16. pii: S1470-2045(17)30730.
    PubMed     Text format    
    
    
    
22. TAMMEMAGI MC, Schmidt H, Martel S, McWilliams A, et al
    Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
    Lancet Oncol. 2017 Oct 16. pii: S1470-2045(17)30597.
    PubMed     Text format     Abstract available
    
    
    
23. FAIVRE-FINN C, Ryder WD, Blackhall F
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer? - Authors' reply.
    Lancet Oncol. 2017;18:e556.
    PubMed     Text format    
    
    
    
24. EZE C, Roengvoraphoj O, Dantes M, Manapov F, et al
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
    Lancet Oncol. 2017;18:e555.
    PubMed     Text format    
    
    
    
25. MITIN T, Farrell M, Holland J, Cetnar J, et al
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
    Lancet Oncol. 2017;18:e554.
    PubMed     Text format    
    
    
    
26. ZENG H, Yu J, Yuan S
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
    Lancet Oncol. 2017;18:e553.
    PubMed     Text format    
    
    
    
27. VAN ZANDWIJK N, Pavlakis N, Kao SC, Linton A, et al
    Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
    Lancet Oncol. 2017;18:1386-1396.
    PubMed     Text format     Abstract available
    
    
    
28. PAVEL ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, et al
    Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase
    Lancet Oncol. 2017;18:1411-1422.
    PubMed     Text format     Abstract available
    
    
    September 2017
29. BRUECKL WM
    Treatment choice in EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2017 Sep 25. pii: S1470-2045(17)30684.
    PubMed     Text format    
    
    
    
30. WU YL, Cheng Y, Zhou X, Lee KH, et al
    Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2017 Sep 25. pii: S1470-2045(17)30608.
    PubMed     Text format     Abstract available
    
    
    
31. PLANCHARD D, Smit EF, Groen HJM, Mazieres J, et al
    Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
    Lancet Oncol. 2017 Sep 8. pii: S1470-2045(17)30679.
    PubMed     Text format     Abstract available
    
    
    
32. PERROT M, Wu L, Wu M, Cho BCJ, et al
    Radiotherapy for the treatment of malignant pleural mesothelioma.
    Lancet Oncol. 2017;18:e532-e542.
    PubMed     Text format     Abstract available
    
    
    
33. MAIO M, Scherpereel A, Calabro L, Aerts J, et al
    Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
    Lancet Oncol. 2017;18:1261-1273.
    PubMed     Text format     Abstract available
    
    
    July 2017
34. AKAMATSU H, Takahashi T, Yamamoto N
    Prophylactic cranial irradiation in small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2017;18:e369.
    PubMed     Text format    
    
    
    
35. FAN X, Liang F, Zhu J
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e368.
    PubMed     Text format    
    
    
    
36. WEISS GJ, Lohinai Z
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e367.
    PubMed     Text format    
    
    
    
37. MANAPOV F, Eze C
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e366.
    PubMed     Text format    
    
    
    
38. RUSTHOVEN CG, Kavanagh BD
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e365.
    PubMed     Text format    
    
    
    
39. DEL PAGGIO JC, Sullivan R, Schrag D, Hopman WM, et al
    Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
    Lancet Oncol. 2017;18:887-894.
    PubMed     Text format     Abstract available
    
    
    June 2017
40. BROWER V
    Atezolizumab in advanced non-small-cell lung cancer.
    Lancet Oncol. 2017 Jun 22. pii: S1470-2045(17)30504.
    PubMed     Text format    
    
    
    
41. FAIVRE-FINN C, Snee M, Ashcroft L, Appel W, et al
    Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
    Lancet Oncol. 2017 Jun 19. pii: S1470-2045(17)30318.
    PubMed     Text format     Abstract available
    
    
    
42. FIETKAU R
    Which fractionation of radiotherapy is best for limited-stage small-cell lung cancer?
    Lancet Oncol. 2017 Jun 19. pii: S1470-2045(17)30439.
    PubMed     Text format    
    
    
    
43. SHAW AT, Kim TM, Crino L, Gridelli C, et al
    Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Lancet Oncol. 2017 Jun 8. pii: S1470-2045(17)30339.
    PubMed     Text format     Abstract available
    
    
    May 2017
44. SHAVERDIAN N, Lisberg AE, Bornazyan K, Veruttipong D, et al
    Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
    Lancet Oncol. 2017 May 24. pii: S1470-2045(17)30380.
    PubMed     Text format     Abstract available
    
    
    
45. DAS M
    Brigatinib effective in ALK-positive non-small-cell lung cancer.
    Lancet Oncol. 2017 May 11. pii: S1470-2045(17)30342.
    PubMed     Text format    
    
    
    March 2017
46. GULLEY JL, Rajan A, Spigel DR, Iannotti N, et al
    Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
    Lancet Oncol. 2017 Mar 31. pii: S1470-2045(17)30240.
    PubMed     Text format     Abstract available
    
    
    
47. TAKAHASHI T, Yamanaka T, Seto T, Harada H, et al
    Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30230.
    PubMed     Text format     Abstract available
    
    
    
48. SLOTMAN BJ
    Time to reconsider prophylactic cranial irradiation in extensive-stage small-cell lung cancer?
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30193.
    PubMed     Text format    
    
    
    
49. BROWER V
    Pravastatin has no advantage in small-cell lung cancer.
    Lancet Oncol. 2017 Mar 9. pii: S1470-2045(17)30184.
    PubMed     Text format    
    
    
    February 2017
50. SCOTT JG, Berglund A, Schell MJ, Mihaylov I, et al
    A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
    Lancet Oncol. 2017;18:202-211.
    PubMed     Text format     Abstract available
    
    
    January 2017
51. BURKI TK
    Treatment options not taken for non-small-cell lung cancer.
    Lancet Oncol. 2017 Jan 27. pii: S1470-2045(17)30066.
    PubMed     Text format    
    
    
    
52. MAYOR S
    Osimertinib effective in EGFR T790M-positive lung cancer.
    Lancet Oncol. 2017;18:e9.
    PubMed     Text format    
    
    
    December 2016
53. BROWER V
    Onartuzumab ineffective in non-small-cell lung cancer.
    Lancet Oncol. 2016 Dec 22. pii: S1470-2045(16)30680.
    PubMed     Text format    
    
    
    
54. RUDIN CM, Pietanza MC, Bauer TM, Ready N, et al
    Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30565.
    PubMed     Text format     Abstract available
    
    
    
55. HELLMANN MD, Rizvi NA, Goldman JW, Gettinger SN, et al
    Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30624.
    PubMed     Text format     Abstract available
    
    
    
56. LIN JJ, Shaw AT
    Raising the bar on first-line immunotherapy in lung cancer.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30594.
    PubMed     Text format    
    
    
    
57. ROSSI A
    Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer.
    Lancet Oncol. 2016 Dec 2. pii: S1470-2045(16)30575.
    PubMed     Text format    
    
    
    November 2016
58. GADGEEL SM
    Drug selection for anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Lancet Oncol. 2016 Nov 7. pii: S1470-2045(16)30567.
    PubMed     Text format    
    
    
    
59. GETTINGER SN, Bazhenova LA, Langer CJ, Salgia R, et al
    Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Lancet Oncol. 2016 Nov 7. pii: S1470-2045(16)30392.
    PubMed     Text format     Abstract available
    
    
    
60. NEAL JW, Dahlberg SE, Wakelee HA, Aisner SC, et al
    Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
    Lancet Oncol. 2016 Nov 4. pii: S1470-2045(16)30561.
    PubMed     Text format     Abstract available
    
    
    
61. ROSELL R, Karachaliou N
    RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer.
    Lancet Oncol. 2016 Nov 4. pii: S1470-2045(16)30557.
    PubMed     Text format    
    
    
    
62. DRILON A, Rekhtman N, Arcila M, Wang L, et al
    Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
    Lancet Oncol. 2016 Nov 4. pii: S1470-2045(16)30562.
    PubMed     Text format     Abstract available
    
    
    October 2016
63. GOMEZ DR, Blumenschein GR Jr, Lee JJ, Hernandez M, et al
    Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.
    Lancet Oncol. 2016 Oct 24. pii: S1470-2045(16)30532.
    PubMed     Text format     Abstract available
    
    
    
64. GOSS G, Tsai CM, Shepherd FA, Bazhenova L, et al
    Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
    Lancet Oncol. 2016 Oct 14. pii: S1470-2045(16)30508.
    PubMed     Text format     Abstract available
    
    
    
65. LANGER CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, et al
    Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Lancet Oncol. 2016 Oct 10. pii: S1470-2045(16)30498.
    PubMed     Text format     Abstract available
    
    
    
66. LE PECHOUX C
    PCI in resected small-cell lung cancer - Author's reply.
    Lancet Oncol. 2016;17:e416.
    PubMed     Text format    
    
    
    
67. KNISELY J, Sharma R, Goenka A, Halthore A, et al
    PCI in resected small-cell lung cancer.
    Lancet Oncol. 2016;17:e415.
    PubMed     Text format    
    
    
    September 2016
68. UMEWENI N, Knight H, McVeigh G
    NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer.
    Lancet Oncol. 2016 Sep 27. pii: S1470-2045(16)30488.
    PubMed     Text format    
    
    
    
69. WALLINGTON M, Saxon EB, Bomb M, Smittenaar R, et al
    30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.
    Lancet Oncol. 2016;17:1203-16.
    PubMed     Text format     Abstract available
    
    
    August 2016
70. BURKI TK
    Predicting lung cancer prognosis using machine learning.
    Lancet Oncol. 2016 Aug 25. pii: S1470-2045(16)30436.
    PubMed     Text format    
    
    
    
71. HALL CJ, Umeweni N, Knight H, Smith L, et al
    NICE guidance on ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer.
    Lancet Oncol. 2016 Aug 23. pii: S1470-2045(16)30435.
    PubMed     Text format    
    
    
    
72. TAN WL, Jain A, Takano A, Newell EW, et al
    Novel therapeutic targets on the horizon for lung cancer.
    Lancet Oncol. 2016;17:e347-62.
    PubMed     Text format     Abstract available
    
    
    
73. LICHT PB, Andersen C, Dan Jorgensen O, Bendixen M, et al
    Quality of life after video-assisted surgery for lung cancer - Author's reply.
    Lancet Oncol. 2016;17:e318-9.
    PubMed     Text format    
    
    
    
74. NAKAZAWA S, Shimizu K, Nagashima T, Mogi A, et al
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e318.
    PubMed     Text format    
    
    
    
75. THE VIOLET TRIALISTS CORRESPON
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e317.
    PubMed     Text format    
    
    
    
76. VERONESI G, Novellis P, Park B
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e316-7.
    PubMed     Text format    
    
    
    
77. MEHRAN RJ, Roth JA
    Quality of life after video-assisted surgery for lung cancer.
    Lancet Oncol. 2016;17:e315-6.
    PubMed     Text format    
    
    
    July 2016
78. PECHOUX CL, Sun A, Slotman BJ, De Ruysscher D, et al
    Prophylactic cranial irradiation for patients with lung cancer.
    Lancet Oncol. 2016;17:e277-93.
    PubMed     Text format     Abstract available
    
    
    June 2016
79. GOTO K, Ohe Y, Shibata T, Seto T, et al
    Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)30104.
    PubMed     Text format     Abstract available
    
    
    
80. KALEMKERIAN GP
    Combination chemotherapy for relapsed small-cell lung cancer.
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)30160.
    PubMed     Text format    
    
    
    
81. BALDWIN DR, Devaraj A
    Lung cancer risk in new pulmonary nodules: implications for CT screening and nodule management.
    Lancet Oncol. 2016 Jun 6. pii: S1470-2045(16)30134.
    PubMed     Text format    
    
    
    
82. WALTER JE, Heuvelmans MA, de Jong PA, Vliegenthart R, et al
    Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial.
    Lancet Oncol. 2016 Jun 6. pii: S1470-2045(16)30069.
    PubMed     Text format     Abstract available
    
    
    
83. ANTONIA SJ, Lopez-Martin JA, Bendell J, Ott PA, et al
    Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30098.
    PubMed     Text format     Abstract available
    
    
    
84. LI Y, Wu YL
    Immunotherapy for small-cell lung cancer.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30159.
    PubMed     Text format    
    
    
    
85. GOLDBERG SB, Gettinger SN, Mahajan A, Chiang AC, et al
    Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30053.
    PubMed     Text format     Abstract available
    
    
    
86. PLANCHARD D, Besse B, Groen HJ, Souquet PJ, et al
    Dabrafenib plus trametinib in patients with previously treated BRAF-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
    Lancet Oncol. 2016 Jun 3. pii: S1470-2045(16)30146.
    PubMed     Text format     Abstract available
    
    
    May 2016
87. BENDIXEN M, Jorgensen OD, Kronborg C, Andersen C, et al
    Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial.
    Lancet Oncol. 2016 May 6. pii: S1470-2045(16)00173.
    PubMed     Text format     Abstract available
    
    
    April 2016
88. VANSTEENKISTE JF, Cho BC, Vanakesa T, De Pas T, et al
    Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2016 Apr 27. pii: S1470-2045(16)00099.
    PubMed     Text format     Abstract available
    
    
    
89. QUOIX E
    Post-operative survival of patients with lung cancer.
    Lancet Oncol. 2016 Apr 27. pii: S1470-2045(16)30031.
    PubMed     Text format    
    
    
    
90. PARK K, Tan EH, O'Byrne K, Zhang L, et al
    Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
    Lancet Oncol. 2016 Apr 12. pii: S1470-2045(16)30033.
    PubMed     Text format     Abstract available
    
    
    
91. PLANCHARD D, Kim TM, Mazieres J, Quoix E, et al
    Dabrafenib in patients with BRAF-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
    Lancet Oncol. 2016 Apr 11. pii: S1470-2045(16)00077.
    PubMed     Text format     Abstract available
    
    
    March 2016
92. FIELD JK, Duffy SW
    Lung cancer CT screening: is annual screening necessary?
    Lancet Oncol. 2016 Mar 18. pii: S1470-2045(16)00079.
    PubMed     Text format    
    
    
    
93. PATZ EF JR, Greco E, Gatsonis C, Pinsky P, et al
    Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial.
    Lancet Oncol. 2016 Mar 18. pii: S1470-2045(15)00621.
    PubMed     Text format     Abstract available
    
    
    
94. KIM DW, Mehra R, Tan DS, Felip E, et al
    Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
    Lancet Oncol. 2016 Mar 10. pii: S1470-2045(15)00614.
    PubMed     Text format     Abstract available
    
    
    
95. BURKI TK
    Counting the cost of end-of-life cancer care.
    Lancet Oncol. 2016;17:e91.
    PubMed     Text format    
    
    
    
96. GARON EB
    The race for combined checkpoint inhibition in NSCLC.
    Lancet Oncol. 2016;17:259-60.
    PubMed     Text format    
    
    
    February 2016
97. TEMEL JS, Abernethy AP, Currow DC, Friend J, et al
    Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.
    Lancet Oncol. 2016 Feb 19. pii: S1470-2045(15)00558.
    PubMed     Text format     Abstract available
    
    
    
98. ANTONIA S, Goldberg SB, Balmanoukian A, Chaft JE, et al
    Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Lancet Oncol. 2016 Feb 5. pii: S1470-2045(15)00544.
    PubMed     Text format     Abstract available
    
    
    
99. CHANG JY, Senan S, Smit EF, Roth JA, et al
    Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2016;17:e42-3.
    PubMed     Text format    
    
    
    
100. KATZ MS, Husain ZA
     Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer.
     Lancet Oncol. 2016;17:e41-2.
     PubMed     Text format    
     
     
     
101. RIESTERER O, Weder W, Stahel R
     Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power? - Authors' reply.
     Lancet Oncol. 2016;17:e44-5.
     PubMed     Text format    
     
     
     
102. RIMNER A, Simone CB 2nd, Zauderer MG, Cengel KA, et al
     Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?
     Lancet Oncol. 2016;17:e43-4.
     PubMed     Text format    
     
     
     
103. HARDING E
     The Lake.
     Lancet Oncol. 2016;17:151.
     PubMed     Text format    
     
     
     
104. BAKER H
     Familial risk in patients with carcinoma of unknown primary.
     Lancet Oncol. 2016;17:e48.
     PubMed     Text format    
     
     
     
105. JASSEM J
     Alectinib in crizotinib-resistant, ALK-positive NSCLC.
     Lancet Oncol. 2016;17:134-5.
     PubMed     Text format    
     
     
     December 2015
106. QUOIX E, Lena H, Losonczy G, Forget F, et al
     TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
     Lancet Oncol. 2015 Dec 22. pii: S1470-2045(15)00483.
     PubMed     Text format     Abstract available
     
     
     
107. BUTTS CA, Sangha R
     TIME for a successful cancer vaccine in NSCLC?
     Lancet Oncol. 2015 Dec 22. pii: S1470-2045(15)00554.
     PubMed     Text format    
     
     
     
108. SHAW AT, Gandhi L, Gadgeel S, Riely GJ, et al
     Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
     Lancet Oncol. 2015 Dec 18. pii: S1470-2045(15)00488.
     PubMed     Text format     Abstract available
     
     
     
109. BROWER V
     Afatinib and chemotherapy in non-small-cell lung cancer.
     Lancet Oncol. 2015 Dec 17. pii: S1470-2045(15)00609.
     PubMed     Text format    
     
     
     October 2015
110. FUSI A, Festino L, Botti G, Masucci G, et al
     PD-L1 expression as a potential predictive biomarker.
     Lancet Oncol. 2015;16:1285-7.
     PubMed     Text format    
     
     
     September 2015
111. VASSAL G, Blanc P, Copland C, Pearson A, et al
     Will the revised class waiver list make it?
     Lancet Oncol. 2015;16:e425-6.
     PubMed     Text format    
     
     
     
112. RICE D, Sepesi B, Heymach J, Swisher S, et al
     SABR vs surgery for NSCLC in the media.
     Lancet Oncol. 2015;16:e422.
     PubMed     Text format    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: